Skip to content
Spiritual Quotes – Lifestyle
Author:
Alebund Pharmaceuticals
Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026
October 23, 2026
Alebund Pharma: FDA Clearance for AP308 IgA Nephropathy Treatment
September 8, 2026
Alebund’s AP301 NDA Accepted for Review by China’s NMPA
August 7, 2026
Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia
July 21, 2026
Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board
June 29, 2026